EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen (updated)

ARS Pharmaceuticals

28/06/2024 12:11

(Adds background in paragraph 2, details in paragraphs 3,4)
       June 28 (Reuters) - ARS Pharmaceuticals  SPRY.O  said on
Friday the European Medicines Agency (EMA) has recommended the
approval of its needle-free emergency treatment, EURneffy, for
allergic reactions.
    EURneffy is seen as an alternative to EpiPen and other
autoinjectors that are filled with epinephrine, a life-saving
drug used by people at risk of anaphylaxis and other allergic
reactions.
    The U.S.-based ARS said the European Commission which
usually follows the EMA's recommendation, is expected to decide
on EURneffy in the third quarter of 2024.
    The nasal spray is also under review by the U.S. Food and
Drug Administration, which is expected to decide on approval for
the drug on Oct.2.

 (Reporting by Christy Santhosh; Editing by Nivedita
Bhattacharjee and Shailesh Kuber)
 ((Christy.Santhosh@thomsonreuters.com;))